Wednesday, July 8, 2026

pharma · Metastatic Melanoma · Unresectable Melanoma · IOVA

Iovance Biotherapeutics

Iovance Biotherapeutics is a pharma organization headquartered in San Carlos, USA. It trades on NYSE under ticker IOVA. Primary therapeutic focus areas include Metastatic Melanoma, Unresectable Melanoma, Metastatic Non-S

825 Industrial Rd, Suite 400, San Carlos, California 94070, US HQ
2007 Founded
916 Employees
Public company Type
IOVA · NYSE Ticker
Company details
Status
Public
HQ
825 Industrial Rd, Suite 400, San Carlos, California 94070, US
Founded
2007
Employees
916
Programs
36
Drugs
26
Patents
94
Clinical program

Cyclophosphamide

Phase 2 · small molecule · Metastatic Bladder Urothelial Carcinoma

Cyclophosphamide for Metastatic Bladder Urothelial Carcinoma is a Phase 2 program (small_molecule) at Iovance Biotherapeutics B.V. with 1 ClinicalTrials.gov record(s).

← All Iovance Biotherapeutics B.V. projects Phase 2 small molecule terminated

Internal code I 77218

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Iovance Biotherapeutics B.V.
Phase
Phase 2
Modality
small_molecule
Indication
Metastatic Bladder Urothelial Carcinoma
Status
terminated
Trials
1